Biogen reports Phase IIa data for IPF candidate

In its 3Q17 earnings presentation, Biogen Inc. (NASDAQ:BIIB) said BG00011 (STX-100) achieved "proof of biology" in a Phase IIa trial by showing "substantial" downregulation of the transforming growth factor (TGF) beta pathway as measured by up to 70% inhibition from baseline of phosphorylated SMAD family member 2 (SMAD2; MADH2) on alveolar macrophages from patients with idiopathic pulmonary fibrosis (IPF).

The double-blind, dose-escalation, U.S. trial enrolled 41 IPF patients to receive once-weekly subcutaneous BG00011 or placebo for 8 weeks. The primary endpoint of the trial is safety and secondary endpoints include biomarkers, antibodies and pharmacokinetics...